BioTuesdays

Tandem expands pediatric indication of insulin pump

Tandem Diabetes Care (NASDAQ:TNDM) received FDA clearance of an expanded pediatric indication for the t:slim Insulin Pump, lowering its use to children age 6 and older from children age 12 and older.

The t:slim Pump is the first and only touchscreen insulin pump cleared by the FDA. The expanded pediatric indication applies to the current t:slim pump features, with no changes to the existing user interface.

“The t:slim pump has the look and feel of a modern consumer device, which we believe makes it especially well-suited for school-aged children who have grown up in a world of smartphones and tablets,” Kim Blickenstaff, president and CEO, said in a statement.

The t:slim pump ranks No.1 by pump users in independent patient surveys, according to Q&A USA Connections Surveys 2013-2015.  The streamlined, user-friendly interface provides rapid access to the features people use most, eliminating the need for excessive scrolling and button pressing.

Subscribe

Sign up to our weekly BioTuesdays newsletter.

Subscribe

Sign up to our weekly BioTuesdays newsletter.